Trend
DailyUptrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minBearish
5 minStrong Bullish
Daily trend turns down below $2.28
Key levels
Resistance$3.92
Resistance$3.79
Support$3.64
Support$3.55
Latest news & SEC filings
No headlines in the last 90 days.
Fulcrum Therapeutics is a drug developer in the clinical testing phase, working on pill-form treatments for uncommon inherited conditions. Its main experimental medicine, pociredir, aims to boost fetal hemoglobin as a therapy for sickle cell disease. The company also searches for biological targets that control gene activity, concentrating on blood disorders, and licenses related compounds from CAMP4 Therapeutics. It is based in the United States and targets patients with rare illnesses, mainly through blood specialists.
Based on the company's 10-K filed Feb 24, 2026.
Nasdaq · Healthcare
SEPT Low Target
$3.00
SEPT Mid Target
$3.00
SEPT High Target
$4.00
Analyst Consensus
$3.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for FULC.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$4.83
27
Moat Score
NONE
3/9
Piotroski Score
-1.9
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
2752.1%
3yr Revenue CAGR
61.0%
EPS Growth YoY
-637.5%
FCF Growth YoY
-2319.0%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for FULC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:21 | $3.77 | 32,326 | $$122K | SELL |
| 20:59:31 | $3.77 | 1,400 | $$5K | MIDPOINT |
| 20:59:31 | $3.77 | 1,104 | $$4K | MIDPOINT |
| 20:59:31 | $3.77 | 1,200 | $$5K | MIDPOINT |
| 20:59:19 | $3.77 | 3,600 | $$14K | BUY |
5 dark pool trades shown · $$149K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Fulcrum Therapeutics, Inc. (FULC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Fulcrum Therapeutics, Inc. (FULC) is at $3.77, up 2.45% (+$0.09) at the Nov 13, 2026 close.
The average analyst price target for FULC is $3.00, ranging from $3 to $4, based on 5 analysts. Latest: HC Wainwright & Co. downgrade on Jun 2, 2026.
Analyst ratings for FULC: 0 Buy, 0 Hold, 6 Sell — consensus Sell.
FULC last reported on Jul 30, 2026: EPS -$0.34 vs -$0.24 expected — a miss of 39.7%.
FULC does not currently pay a dividend.
Support: $3.64, $3.55, $3.47. Resistance: $3.79, $3.92, $4.01.
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.